Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP David Altshuler sold 1,796 shares of the company’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $160.00, for a total transaction of $287,360.00. Following the transaction, the executive vice president now owns 107,807 shares of the company’s stock, valued at approximately $17,249,120. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Shares of Vertex Pharmaceuticals Incorporated (VRTX) opened at 157.08 on Thursday. The firm has a market capitalization of $39.60 billion, a PE ratio of 150.89 and a beta of 1.75. Vertex Pharmaceuticals Incorporated has a 1-year low of $71.46 and a 1-year high of $167.85. The firm’s 50 day moving average is $155.53 and its 200 day moving average is $124.16.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.33. The business had revenue of $544.10 million during the quarter, compared to analyst estimates of $489.95 million. Vertex Pharmaceuticals had a return on equity of 4.64% and a net margin of 12.05%. The firm’s revenue was up 26.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.24 EPS. Analysts anticipate that Vertex Pharmaceuticals Incorporated will post $1.60 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/09/07/david-altshuler-sells-1796-shares-of-vertex-pharmaceuticals-incorporated-vrtx-stock.html.

A number of equities analysts have commented on the stock. UBS AG restated a “buy” rating and set a $135.00 price objective (up previously from $132.00) on shares of Vertex Pharmaceuticals in a research report on Friday, May 19th. Stifel Nicolaus upped their price objective on shares of Vertex Pharmaceuticals from $130.00 to $154.00 and gave the stock a “buy” rating in a research report on Tuesday, July 18th. Robert W. Baird restated an “outperform” rating and set a $171.00 price objective (up previously from $136.00) on shares of Vertex Pharmaceuticals in a research report on Friday, July 21st. Cowen and Company restated a “market perform” rating and set a $105.00 price objective on shares of Vertex Pharmaceuticals in a research report on Thursday, July 6th. Finally, J P Morgan Chase & Co set a $175.00 price objective on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, July 19th. Six investment analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $162.88.

Several institutional investors have recently made changes to their positions in VRTX. Korea Investment CORP lifted its holdings in shares of Vertex Pharmaceuticals by 225.3% during the 1st quarter. Korea Investment CORP now owns 950 shares of the pharmaceutical company’s stock valued at $104,000 after buying an additional 658 shares during the last quarter. Guardian Life Insurance Co. of America lifted its holdings in shares of Vertex Pharmaceuticals by 0.6% during the 1st quarter. Guardian Life Insurance Co. of America now owns 956 shares of the pharmaceutical company’s stock valued at $105,000 after buying an additional 6 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Vertex Pharmaceuticals by 15.4% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 988 shares of the pharmaceutical company’s stock valued at $127,000 after buying an additional 132 shares during the last quarter. FNY Partners Fund LP lifted its holdings in shares of Vertex Pharmaceuticals by 900.0% during the 2nd quarter. FNY Partners Fund LP now owns 1,000 shares of the pharmaceutical company’s stock valued at $128,000 after buying an additional 900 shares during the last quarter. Finally, Dupont Capital Management Corp acquired a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter valued at about $186,000. Institutional investors and hedge funds own 92.88% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Stock Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related stocks with our FREE daily email newsletter.